Your browser doesn't support javascript.
loading
Vaccine value profile for Hookworm.
Puchner, Karl Philipp; Bottazzi, Maria Elena; Periago, Victoria; Grobusch, Martin; Maizels, Rick; McCarthy, James; Lee, Bruce; Gaspari, Erika; Diemert, David; Hotez, Peter.
Affiliation
  • Puchner KP; Policy Cures Research, Sydney, Australia. Electronic address: karlphilipppuchner@gmail.com.
  • Bottazzi ME; National School of Tropical Medicine, Baylor College of Medicine, Baylor, TX, USA.
  • Periago V; Fundación Mundo Sano, Buenos Aires, Argentina.
  • Grobusch M; Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, Amsterdam Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, The Netherlands.
  • Maizels R; Wellcome Centre for Integrative Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
  • McCarthy J; The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Lee B; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
  • Gaspari E; European & Developing Countries Clinical Trials Partnership (EDCTP), The Hague, The Netherlands.
  • Diemert D; Department of Microbiology, Immunology & Tropical Medicine, George Washington University Medical Center, Washington, DC, USA.
  • Hotez P; National School of Tropical Medicine, Baylor College of Medicine, Baylor, TX, USA.
Vaccine ; 2023 Oct 18.
Article in En | MEDLINE | ID: mdl-37863671
ABSTRACT
Hookworm, a parasitic infection, retains a considerable burden of disease, affecting the most underprivileged segments of the general population in endemic countries and remains one of the leading causes of mild to severe anemia in Low and Middle Income Countries (LMICs), particularly in pregnancy and children under 5. Despite repeated large scale Preventive Chemotherapy (PC) interventions since more than 3 decades, there is broad consensus among scholars that elimination targets set in the newly launched NTD roadmap will require additional tools and interventions. Development of a vaccine could constitute a promising expansion of the existing arsenal against hookworm. Therefore, we have evaluated the biological and implementation feasibility of the vaccine development as well as the added value of such a novel tool. Based on pipeline landscaping and the current knowledge on key biological aspects of the pathogen and its interactions with the host, we found biological feasibility of development of a hookworm vaccine to be moderate. Also, our analysis on manufacturing and regulatory issues as well as potential uptake yielded moderate implementation feasibility. Modelling studies suggest a that introduction of a vaccine in parallel with ongoing integrated interventions (PC, WASH, shoe campaigns), could substantially reduce burden of disease in a cost - saving mode. Finally a set of actions are recommended that might impact positively the likelihood of timely development and introduction of a hookworm vaccine.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Vaccine Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Vaccine Year: 2023 Document type: Article
...